MA71255A - Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 - Google Patents

Composés pour le traitement de l'ataxie spinocérébelleuse de type 3

Info

Publication number
MA71255A
MA71255A MA71255A MA71255A MA71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A
Authority
MA
Morocco
Prior art keywords
compounds
treatment
spinocerebellar ataxia
ataxia type
type
Prior art date
Application number
MA71255A
Other languages
English (en)
Inventor
Jana Narasimhan
Nanjing Zhang
Xiaoyan Zhang
Anuradha Bhattacharyya
Guangming Chen
Yao JIANG
Matthew G. Woll
Michael A. Arnold
James R. ANNAND
Gayan Mirihana ARACHCHILAGE
Jackie CHIU
Gaurav Dahiya
Arun Raj KIZHAKKAYIL MANGADAN
Christie Morrill
Stephen E. MOTIKA
Original Assignee
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.
Publication of MA71255A publication Critical patent/MA71255A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA71255A 2022-06-22 2023-06-20 Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 MA71255A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263354339P 2022-06-22 2022-06-22
PCT/US2023/068717 WO2023250316A1 (fr) 2022-06-22 2023-06-20 Composés pour le traitement de l'ataxie spinocérébelleuse de type 3
EP23827977.2A EP4543444A4 (fr) 2022-06-22 2023-06-20 Composés pour le traitement de l'ataxie spinocérébelleuse de type 3

Publications (1)

Publication Number Publication Date
MA71255A true MA71255A (fr) 2025-04-30

Family

ID=89380638

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71255A MA71255A (fr) 2022-06-22 2023-06-20 Composés pour le traitement de l'ataxie spinocérébelleuse de type 3

Country Status (15)

Country Link
US (1) US20250382305A1 (fr)
EP (1) EP4543444A4 (fr)
JP (1) JP2025521545A (fr)
KR (1) KR20250035623A (fr)
CN (1) CN119997954A (fr)
AU (1) AU2023289366A1 (fr)
CA (1) CA3259536A1 (fr)
CL (1) CL2024003939A1 (fr)
CO (1) CO2024017547A2 (fr)
CR (1) CR20240567A (fr)
IL (1) IL317705A (fr)
MA (1) MA71255A (fr)
MX (1) MX2024015863A (fr)
PE (1) PE20250836A1 (fr)
WO (1) WO2023250316A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (fr) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale
WO2026019945A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019918A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019928A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019917A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019936A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019931A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019930A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019893A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019914A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019950A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2026019946A1 (fr) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912245A2 (pt) * 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
WO2012044993A1 (fr) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés, compositions pharmaceutiques, et procédés de traitement ou de prévention de maladies ou de troubles neurodégénératifs
MA39987A (fr) * 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
SG11202108519TA (en) * 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
EP3929185A4 (fr) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Composé cyclique condensé contenant de l'azote, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
AU2023289366A1 (en) 2025-01-23
IL317705A (en) 2025-02-01
JP2025521545A (ja) 2025-07-10
US20250382305A1 (en) 2025-12-18
CN119997954A (zh) 2025-05-13
CO2024017547A2 (es) 2025-03-27
EP4543444A1 (fr) 2025-04-30
CA3259536A1 (fr) 2023-12-28
KR20250035623A (ko) 2025-03-12
CL2024003939A1 (es) 2025-05-02
WO2023250316A1 (fr) 2023-12-28
MX2024015863A (es) 2025-04-02
CR20240567A (es) 2025-03-03
EP4543444A4 (fr) 2026-04-29
PE20250836A1 (es) 2025-03-21

Similar Documents

Publication Publication Date Title
MA71255A (fr) Composés pour le traitement de l'ataxie spinocérébelleuse de type 3
EP4288059A4 (fr) Composés pour le traitement de l'ataxie spinocérébelleuse de type 3
EP4301359A4 (fr) Composés de liaison covalents pour le traitement d'une maladie
EP4288441A4 (fr) Procédés de traitement de l'ataxie spinocérébelleuse de type 3
EP3986863A4 (fr) Inhibiteurs de glycolate oxydase pour le traitement d'une maladie
EP3755804A4 (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA52747A (fr) Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
EP3927705A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles neurodégénératifs
MA55973A (fr) Composé pour le traitement de la goutte ou de l'hyperuricémie
EP3986409A4 (fr) Inhibiteurs de l'uridine phosphorylase (upase) pour le traitement de pathologies hépatiques
EP4192453A4 (fr) Utilisation de dexpramipexole pour le traitement de l'asthme modéré à sévère
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP4301132A4 (fr) Inhibiteur de rock2 pour le traitement d'une infection virale
EP4200402A4 (fr) Développement de nouvelles thérapies géniques pour traiter la perte osseuse due à l'inflammation
EP4232075A4 (fr) Composés, compositions et méthodes d'utilisation pour le traitement de spondylodèses
EP3931178A4 (fr) Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire
EP3883552A4 (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
EP4274583A4 (fr) Procédés et composés destinés au traitement de l'ataxie de friedreich
EP4121403A4 (fr) Composés nitro-aminoadamantane pour le traitement d'infections par le bêtacoronavirus
EP4181915A4 (fr) Compositions pour le traitement de l'obésité
EP3996729C0 (fr) Composition pour la prévention ou le traitement de la dépression ou de l'anxiété
EP4143218A4 (fr) Composés pour la prévention et le traitement d'un dysfonctionnement cognitif de soins post-intensifs et d'un dysfonctionnement cognitif résultant d'une détresse respiratoire
EP4149469A4 (fr) Utilisation de composés pour le traitement d'infections virales
EP4288054A4 (fr) Procédés de traitement de l'ataxie spinocérébelleuse de type 3
EP3826633A4 (fr) Compositions pour le traitement de l'hypertension